CytomX Therapeutics (CTMX) Operating Expenses (2014 - 2026)

CytomX Therapeutics' Operating Expenses history runs 13 years deep, the most recent figure standing at $29.9 million for Q1 2026.

• Quarterly Operating Expenses rose 5.77% year-over-year to $29.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $100.2 million (down 10.21% YoY) and the FY2025 annual result came in at $98.6 million, down 12.86% from the prior year.
• Operating Expenses was $29.9 million for Q1 2026 at CytomX Therapeutics, up from $28.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $42.9 million in Q2 2022 and bottomed at $19.9 million in Q2 2025.
• A 5-year average of $29.6 million and a median of $29.2 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses slumped 43.07% — and 2025, when it surged 40.08%.
• CytomX Therapeutics' Operating Expenses stood at $29.6 million in 2022, then slipped by 8.16% to $27.2 million in 2023, then slipped by 24.98% to $20.4 million in 2024, then surged by 40.08% to $28.6 million in 2025, then gained by 4.67% to $29.9 million in 2026.
• Business Quant data shows CTMX's Operating Expenses at $29.9 million in Q1 2026, $28.6 million in Q4 2025, and $21.7 million in Q3 2025.